SBIR/STTR Research Award
Niclosamide Formulations for the Treatment of Influenza Infections
Award amount
$298,479Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MOLECULAR EXPRESS, INC
- Proposal award date
- 2022-07-08
- Contract end date
- 2023-06-30
- UEI
- R1JMHFESEKD5
- Solicitation number
- PA20-260
- Topic code
- NIAID
Research abstract
Project SummaryThe principal goal of this project is to demonstrate that the FDA-approved anthelminthic drug,
niclosamide, can be reformulated in a synthetic lung surfactant which can be aerosolized for the treatment of
infections caused by respiratory viruses. The studies proposed in this SBIR Phase I application will be focused
on testing this concept by suspending niclosamide loaded liposomes in our proprietary lung surfactant
technology (Niclosurf) and testing candidate Niclosurf formulations in a mouse influenza challenge model. The
effectiveness of Niclosurf as a treatment for respiratory viral infections caused by influenza will be evaluated.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
- DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS
- Development of a VesiVax TLR7 Formula as an Effective Adjuvant
- DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
- VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
55 SBIR/STTR records share this UEI (1998–2024). Reported award amounts total $36,762,517. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense